Drugs / ExPEC4V
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02748967 | Apr → Aug 2016 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03819049 | Jun 2019 → Jun 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03500679 | May → Nov 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02546960 | Nov 2015 → Sep 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02289794 Comparator | Jan 2014 → Jul 2015 | escherichia coli infection | GlycoVaxyn AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ExPEC4V | “We randomly assigned (1:1) healthy adult women with a history of recurrent urinary tract infection (UTI) to receive a single injection of either intramuscular ExPEC4V or placebo.” PMID 28238601 ↗ Feb 2017 |
| Modality | Vaccine | “a bioconjugate vaccine containing the O-antigens of four E coli serotypes (ExPEC4V)” PMID 28238601 ↗ Feb 2017 |
| Route | Intramuscular | “a single injection of either intramuscular ExPEC4V or placebo” PMID 28238601 ↗ Feb 2017 |